CTLA4 and non-small cell lung carcinoma: A clear correlation between a favorable therapeutic outcome of ICIs, such as anti-CTLA4 and anti-PD1, and mutational burden have been identified in several cancer types, including non-small cell lung cancer (NSCLC), melanoma, and bladder cancer [15].